Head-to-head · free

Rhythm Pharmaceuticals, Inc. vs Sight Sciences, Inc.

RYTM vs SGHT — return on capital, cash generation, margins and balance sheet side by side.

RYTM

4 / 9

measures where RYTM leads

SGHT

5 / 9

measures where SGHT leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureRYTM · FY2025SGHT · FY2025
Revenue$189.8M$77.4M
Net income(196.5M)(38.4M)
Revenue growth (yearly, multi-year)56.5%12.1%
Free cash flow(116.6M)(29.9M)
Free cash flow margin-61.5%-38.7%
Net cash / (debt)——
ROIC——
Return on equity-251.1%-50.7%
Gross margin89.7%86.2%
Operating margin-101.2%-48.0%
Net debt / EBITDA0.28x1.41x

Figures are as reported by each company; latest fiscal year shown.

Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$953000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full RYTM profile →

Where Sight Sciences, Inc.'s cash went (FY2025)

Capital spending
$224000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full SGHT profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons